Stay updated with breaking news from Janseen research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer Decision follows mixed results from the phase 3 ACIS study Johnson & Johnson’s (J&J) pharma division Janssen has announced that it will not pursue regulatory submissions for a combination of its androgen receptor inhibitor Erleada and hormonal therapy Zytiga in prostate cancer. Specifically, Janssen will not pursue regulatory approval based on the phase 3 ACIS study, which evaluated Erleada (apalutamide) and Zytiga (abiraterone acetate) plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). The ACIS study met its primary endpoint of radiographic progression-free survival (rPFS), with a 31% reduction in the risk of radiographic progression or death in these patients. ....